Neurizon Therapeutics Limited has released a press release.
PharmAust receives ethics approval to begin Phase II Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Epichem Final Loan Repayment Milestone for New Laboratory
- PharmAust Commences GMP Tablet Manufacture for Phase 2 Trial
- Receipt of 25kg of GMP-Grade Monepantel from Elanco
- Phase I Canine Repeat Dose MPL Demonstrates High Performance
- PharmAust Receives $672,250 R&D Tax Incentive Refund
Later from Neurizon Therapeutics
- Response to ASX Price and Volume Query
- Receipt of GMP Grade Tablets for Phase II Trials
- Preliminary Final Report
- Investor Roadshow Presentation - September 2019
- Phase II Dog Cancer Trial Commences
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics